Table 2.
Clinical, biological and genetic features, cell lineage phenotypes and related cell lines of the most used NB cell lines.
| Cell line | Gender | Age | INSS stage | Origin site | Treatment | Phenotype | Mycn status | Ch 1p status | Ch 11q status | Ch 17q status | Related cell lines | References |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-N-SH | F | 4 y | 4 | Bone marrow | CT/RT | I | Non-amplified | Normal | Normal | Gain | Sublines SH-SY5Y/SH-EP | 68,130,132,133 |
| BE(2)-C | M | 25 mo | 4 | Bone marrow | CT/RT | I | Amplified | – | – | Parental SK-N-BE(2) | 65,69,130,134,135 | |
| NB9 | M | 22 mo | 4 | Adrenal gland | None | I | Amplified | Loss | Normal | – | – | 130,132,136 |
| SH-SY-5Y | F | 4 y | 4 | Bone marrow | CT/RT | N | Non-amplified | Normal | Normal | Gain | Parental SK-N-SH | 65,67,126,133 |
| SK-N-BE (1) | M | 20 mo | 4 | Bone marrow | None | N | amplified | Loss | - | Normal | SK-N-BE (2) | 65,128,130,134,135 |
| SK-N-BE(2) | M | 24 mo | 4 | Bone marrow | CT/RT | N | Amplified | Loss | Normal | Gain | Pre-therapy SK-N-BE(1) | 128,132,135,137 |
| BE(2)-M17 | M | 24 mo | 4 | Bone marrow | CT/RT | N | Amplified | Loss | Normal | Gain | Parental SK-N-BE(2) | 65,66,130 |
| SMS-KCN | M | 11 mo | 4 | Adrenal gland | None | N | Amplified | Loss | – | Gain | Post-therapy SMS-KCNR | 65,128,132 |
| IMR-32 | M | 13 mo | _ | Abdominal mass | None | N | Amplified | Loss | Normal | – | – | 65,132,133,138 |
| SK-N-FI | M | 11 y | 4 | Bone marrow | CT | N | Non-amplified | Normal | Normal | Normal | – | 34,139–141 |
| SH-EP | F | 4 y | 4 | Bone marrow | CT/RT | S | Non-amplified | Normal | Normal | Gain | Parental SK-N-SH | 66,68,87 |
| SK-N-AS | F | 8 y | 4 | Bone marrow | - | S | Non-amplified | Loss | Gain | – | 130,139,141,142 | |
| SK-N-MC | F | 14 y | 4 | Supra-orbital lymph node | CT/RT | S | Amplified | Loss | Normal | Subline SK-N-MC-IXC | 132,139,142 | |
| CHLA-20 | F | 24 mo | 4 | Bone marrow | CT | – | Non-amplified | – | – | Normal | Pre-therapy CHLA-15 | 128,131,133 |
| NB1643 | _ | 36 mo | 4 | Retroperitoneal mass | None | – | Amplified | Loss | – | Normal | – | 140,143 |
| NB19 | F | 12 mo | 4 | Bone marrow | CT | – | Amplified | Loss | – | – | – | 130,132 |
Note: BM: bone marrow; AG: adrenal gland; INSS: International Neuroblastoma Staging System; AM: abdominal mass; RM: retroperitoneal mass; LN: lymph node; CT: chemotherapy; RT: radiotherapy; AMN: amplified MYCN; NAMN: non-amplified MYCN; (−): non determined.